103345Developing Clostridium as a Novel Secretion System for Therapeutic PeptidesClosedCollaborative R&DInnovate UKCHAIN Biotechnology Ltd. and the University of Nottingham are developing Clostridia bacteria for the healthcare market targeting C. difficile infections and chronic diseases like inflammatory bowel disease. The bug is a live biotherapeutic product. Success on the project will transform existing treatments for chronic gut-related diseases benefiting the lives of millions of sufferers around the world.